Lipitor

Atorvastatin, the active ingredient in Lipitor, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It treats hypercholesterolemia, mixed dyslipidemia and helps prevent cardiovascular events in adults.

GNH USA supplies Lipitor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atorvastatin acts on lipid metabolism pathways to lower abnormal blood lipids. - Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. - Mixed dyslipidemia: lowers triglycerides and raises HDL‑cholesterol while decreasing LDL‑cholesterol. - Prevention of cardiovascular events: lowers risk of myocardial infarction, stroke and related events in at‑risk patients.

Atorvastatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate pain often reported. - Myalgia: muscle aches or weakness without significant injury. - Abdominal pain: discomfort in the stomach area. - Nausea: feeling of queasiness or urge to vomit.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to kidney injury. - Elevated liver enzymes: indicating possible hepatic stress. - Severe allergic reactions: such as rash, swelling, or anaphylaxis.

Before initiating therapy, consider the following safety measures. - Pregnancy: contraindicated (Category X) due to risk of fetal harm. - Liver disease: avoid use or monitor hepatic enzymes closely. - Renal impairment: dose may require adjustment based on kidney function. - Drug interactions: review concomitant medications, especially strong CYP3A4 inhibitors. - Monitoring: periodic lipid profile and liver function tests are recommended. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Atorvastatin can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors): may increase atorvastatin plasma levels and risk of toxicity. - Gemfibrozil or high‑dose niacin: can markedly raise risk of myopathy.

Moderate Interactions (Monitor Closely): - Other statins: combined therapy may increase muscle toxicity. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Cyclosporine or amiodarone: can raise atorvastatin concentrations modestly.